TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: RPR titer increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closeness of chosen plan to ideal plan
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difficulty in decision making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severe haemodynamic depression
Endpoint domain: Adverse events/effects
Primary endpoint: Ovarian response to COH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation, atrial flutter or atrial tachycardia (AF/AT) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unplanned medical visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of erythema, tension, itching, and burning sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of post-lesional hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HF normalized units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial colonisation on the toothbrushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction of mortality
Endpoint domain: Mortality/survival
Primary endpoint: incidence of permanent ATA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality during hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Strain rate propagation velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amygdala–hippocampal connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: feelings of stigmatization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean reduction in psoriasis area-and-severity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients clear or almost clear of psoriasis after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe nephrotoxicity requiring drug withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Back pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of HAPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ΔASPI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Freedom from death, myocardial infarction, stroke, or emergency surgery
Endpoint domain: Mortality/survival
Primary endpoint: MR reduction of at least 1.0 grade or reduction of regurgitant orifice area by 0.1 cm(2) or regurgitant volume by 15 mL or regurgitant fraction by 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum induced dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Antibody response to hepatitis B immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NIBRG-14-specific seroprotection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum IgG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: protection from febrile responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of CSF repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to readiness for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of cesarean section
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of operative vaginal delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of attributing an SAE to a drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma leukotriene B4 (LTB4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PGF1α concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spread of local anaesthetic from one nerve to another
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overlap of anaesthetized skin areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average supine QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc interval on tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IM torso rotation strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in student scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehospitalization risk
Endpoint domain: Mortality/survival
Primary endpoint: Composite score on the BISF-W
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in the PDS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with treatment efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in migraine-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall gut transit (% emptied at 6 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urine mannitol excretion at 0-8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool weight over 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean postoperative air-bone gap (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in speech reception threshold (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimates of cardiopulmonary resuscitation survival
Endpoint domain: Mortality/survival
Primary endpoint: Cervical cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death and nonfatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral microcirculation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: peak filling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: end-diastolic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 90-day modified Rankin Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of RPE tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity (VA) outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak anti-Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined rate of operative mortality and severe complications
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Chronic Kidney Disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severity of intestinal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of pulmonary injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Five-year cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: mean cumulative irritancy scores
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed job loss
Endpoint domain: Life impact
Endpoint subdomain: Employment
Primary endpoint: Cmax of cerivastatin lactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (t1/2) of cerivastatin lactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased brain activation during fearful face processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased amygdala responses to fearful faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective feelings of fearfulness and depressiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simultaneous new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Combined unique activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: New T1 gadolinium enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Complement activation via the alternative pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of C3c factor in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Haemocompatibility of polysulfone membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ED visits and hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Likelihood of dying in the RACF
Endpoint domain: Mortality/survival
Primary endpoint: Area of microcrusts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global improvement scores for post-treatment edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global improvement scores for post-treatment wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of PDF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial non-function (INF)
Endpoint domain: Adverse events/effects
Primary endpoint: Vasodilation measured in mL/min/100 mL FAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduced number of wet days weekly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily voiding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable overall response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Significant drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality at 8 weeks
Endpoint domain: Mortality/survival
Primary endpoint: AF recurrences within the first 4 weeks following ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients remaining in sinus rhythm after follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clinical score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased urinary excretion of arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-standard deviation score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma phospholipid profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoiding anxiety and stress‐provoking activity before bed
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Comfort level of mothers using SBP versus CBP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MMP-9 levels in AVM tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean diastolic pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall fluency performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) brain
Endpoint domain: Mortality/survival
Primary endpoint: BG decline during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary glucose excretion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Respiratory status after 4 hours of observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of onset of effect (kout)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident dementia risk
Endpoint domain: Mortality/survival
Primary endpoint: Consumption of postoperative rescue analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Antral CSA after facemask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median total cholesterol sorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma sum of campesterol plus sitosterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: diurnal intraocular pressure (IOP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: percent change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent change in FEF25‐75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent change in Vmax25
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in maximum cystometric capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in maximum detrusor pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in volume at first contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in nasolabial fold severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biliary sepsis requiring emergency surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Need for emergency cholecystectomy and other interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical course improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUM score of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: number of medications needed postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent scores in exit exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BBPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALY) gained
Endpoint domain: Mortality/survival
Primary endpoint: Life Years (LY) gained
Endpoint domain: Mortality/survival
Primary endpoint: release of cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of defibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Cortical activation measured using fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MSNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of good cosmetic result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory esthetic result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of keratoconjunctival epitheliopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient survival at 1, 3, 6, 12, and 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival at 1, 3, 6, 12, and 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Bleb vascularity agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Urapidil plasma-concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histophysiology of secondary lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of skin infections
Endpoint domain: Adverse events/effects
Primary endpoint: Length of center of pressure (COP) projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of center of pressure (COP) projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pressure ulcer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of scratch recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-epithelialization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of flares of vulvovaginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in CCT on postoperative Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of eyes with flare grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postextubation stridor
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant IgE-mediated food hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: grade 2-3 hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to correctly interpret % DV information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ability to mathematically manipulate nutrition information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Elevated openness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of ischemic defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in muscle strength of lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in muscle strength of trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acquisition of new motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral for cancer prevention measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma concentration-time curve (AUC) extrapolated to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC above baseline values (AUC(ab)) for superior mesenteric artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oestradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progesterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Growth hormone levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for identification of esophageal intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for identification of esophageal intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to report ETT placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: syncope recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of macular hole closures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent central scotomata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 year event-free survival (pEFS)
Endpoint domain: Mortality/survival
Primary endpoint: Crash risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentine remineralisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour urinary ammonium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24 hour urinary sulfate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in ESI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes